IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,029,264 | +11.5% | 617,930 | +0.8% | 0.01% | +14.3% |
| Q2 2023 | $25,146,917 | +12.4% | 612,891 | -2.1% | 0.01% | +16.7% |
| Q1 2023 | $22,378,608 | -2.6% | 626,150 | +3.0% | 0.01% | -14.3% |
| Q4 2022 | $22,965,670 | -24.7% | 608,040 | -11.9% | 0.01% | -30.0% |
| Q3 2022 | $30,513,000 | +13.8% | 689,872 | -4.7% | 0.01% | +25.0% |
| Q2 2022 | $26,802,000 | -14.1% | 723,995 | -14.0% | 0.01% | 0.0% |
| Q1 2022 | $31,198,000 | +26.4% | 842,284 | +3.9% | 0.01% | +33.3% |
| Q4 2021 | $24,678,000 | -13.8% | 810,966 | -5.0% | 0.01% | 0.0% |
| Q3 2021 | $28,622,000 | -14.7% | 853,370 | +1.4% | 0.01% | -14.3% |
| Q2 2021 | $33,564,000 | -35.5% | 841,431 | -27.3% | 0.01% | -41.7% |
| Q1 2021 | $52,018,000 | -20.0% | 1,156,999 | +0.5% | 0.01% | -25.0% |
| Q4 2020 | $65,061,000 | +49.4% | 1,150,718 | +25.3% | 0.02% | +33.3% |
| Q3 2020 | $43,561,000 | -23.6% | 918,027 | -5.1% | 0.01% | -29.4% |
| Q2 2020 | $57,042,000 | +24.7% | 967,449 | +0.0% | 0.02% | +6.2% |
| Q1 2020 | $45,733,000 | -26.3% | 967,293 | -5.9% | 0.02% | -5.9% |
| Q4 2019 | $62,083,000 | -0.4% | 1,027,704 | -1.2% | 0.02% | -5.6% |
| Q3 2019 | $62,342,000 | -9.9% | 1,040,580 | -3.3% | 0.02% | -10.0% |
| Q2 2019 | $69,174,000 | -16.2% | 1,076,304 | +5.9% | 0.02% | -20.0% |
| Q1 2019 | $82,521,000 | +34.1% | 1,016,637 | -10.7% | 0.02% | +25.0% |
| Q4 2018 | $61,537,000 | +2.4% | 1,138,308 | -2.3% | 0.02% | +17.6% |
| Q3 2018 | $60,104,000 | +19.3% | 1,165,267 | -3.6% | 0.02% | +13.3% |
| Q2 2018 | $50,366,000 | +0.0% | 1,208,703 | +5.8% | 0.02% | 0.0% |
| Q1 2018 | $50,346,000 | -9.3% | 1,142,168 | +3.5% | 0.02% | -6.2% |
| Q4 2017 | $55,497,000 | -5.1% | 1,103,329 | -4.4% | 0.02% | -11.1% |
| Q3 2017 | $58,510,000 | -1.6% | 1,154,048 | -1.3% | 0.02% | -5.3% |
| Q2 2017 | $59,467,000 | +25.6% | 1,169,015 | -0.7% | 0.02% | +26.7% |
| Q1 2017 | $47,344,000 | -17.4% | 1,177,720 | -1.7% | 0.02% | -25.0% |
| Q4 2016 | $57,318,000 | +84.5% | 1,198,363 | +41.3% | 0.02% | +81.8% |
| Q3 2016 | $31,067,000 | +53.2% | 847,912 | -2.6% | 0.01% | +37.5% |
| Q2 2016 | $20,281,000 | -40.9% | 870,787 | +2.8% | 0.01% | -42.9% |
| Q1 2016 | $34,310,000 | -5.5% | 847,168 | +39.8% | 0.01% | 0.0% |
| Q4 2015 | $36,288,000 | – | 605,927 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |